SK Life Sciences' XCOPRI (cenobamate tablets) Receives the US FDA's Approval for Partial-Onset Seizures in Adults
Shots:
- The approval is based on two global studies (Study 013 and Study 017) assessing XCOPRI vs PBO and demonstrated significant reductions in seizure frequency vs PBO at all doses studied
- Study 013 results: XCOPRI (200 mg/day) (56% vs 22%)- zero seizures (28% vs 9%); Study 017: XCOPRI (100 mg/day). During maintenance phase of 013- 017 reduction in median seizures @ 100/200/400 mg/day (36%- 55%- 55% vs 24 %); (4%- 11%- 21% vs 1%)
- XCOPRI (cenobamate tablets) is an anti-epileptic drug targeted for partial-onset seizures in adults with expected availability in the US in Q2’2020. Additionally- in 2019 SK biopharma signs an exclusive license agreement with Arvelle Therapeutics to develop and commercialize in EU
Click here to read full press release/ article | Ref: PRNewswire | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com